9.50
price up icon0.85%   0.08
after-market アフターアワーズ: 9.52 0.02 +0.21%
loading
前日終値:
$9.42
開ける:
$9.48
24時間の取引高:
3.27M
Relative Volume:
1.17
時価総額:
$967.56M
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-1.7336
EPS:
-5.48
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
-6.86%
1か月 パフォーマンス:
-27.65%
6か月 パフォーマンス:
-65.28%
1年 パフォーマンス:
-63.09%
1日の値動き範囲:
Value
$9.32
$9.6887
1週間の範囲:
Value
$9.25
$10.39
52週間の値動き範囲:
Value
$9.25
$34.87

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1174)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
598
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

NTLA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
9.50 967.56M 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.00 108.68B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
681.58 74.90B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
640.52 38.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.27 31.76B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
111.93 26.83B 3.30B -501.07M 1.03B -2.1146

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
10:00 AM

2025-01-20 | Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing

10:00 AM
pulisher
03:58 AM

Avanza Fonder AB Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

03:58 AM
pulisher
Jan 19, 2025

Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowHere's What Happened - MarketBeat

Jan 19, 2025
pulisher
Jan 19, 2025

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Hennion & Walsh Asset Management Inc. - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace

Jan 18, 2025
pulisher
Jan 17, 2025

Intellia Loses 21.6% in a Week: How Should You Play the Stock? - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha

Jan 17, 2025
pulisher
Jan 17, 2025

2025-01-17 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing

Jan 17, 2025
pulisher
Jan 17, 2025

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance

Jan 17, 2025
pulisher
Jan 16, 2025

(NTLA) Technical Pivots with Risk Controls - Stock Traders Daily

Jan 16, 2025
pulisher
Jan 16, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation - Markets Insider

Jan 16, 2025
pulisher
Jan 16, 2025

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates - Yahoo Finance

Jan 16, 2025
pulisher
Jan 16, 2025

Intellia to submit gene-editing therapy NTLA-2002 to FDA in 2026 - Angioedema News Today

Jan 16, 2025
pulisher
Jan 15, 2025

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach Out - Markets Insider

Jan 15, 2025
pulisher
Jan 15, 2025

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down - MSN

Jan 15, 2025
pulisher
Jan 14, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out - Markets Insider

Jan 14, 2025
pulisher
Jan 14, 2025

Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade) - Seeking Alpha

Jan 14, 2025
pulisher
Jan 14, 2025

2025-01-14 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out | NDAQ:NTLA | Press Release - Stockhouse Publishing

Jan 14, 2025
pulisher
Jan 14, 2025

Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $12.00 by Analysts at The Goldman Sachs Group - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect - AccessWire

Jan 13, 2025
pulisher
Jan 13, 2025

Intellia Therapeutics - The Pharma Letter

Jan 13, 2025
pulisher
Jan 13, 2025

Intellia Therapeutics: Buying The Path To Commercialization (NASDAQ:NTLA) - Seeking Alpha

Jan 13, 2025
pulisher
Jan 13, 2025

13 Analysts Have This To Say About Intellia Therapeutics - Benzinga

Jan 13, 2025
pulisher
Jan 13, 2025

Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $40.00 at Oppenheimer - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Intellia stock target cut at Oppenheimer on program discontinuations - Investing.com

Jan 13, 2025
pulisher
Jan 12, 2025

The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter

Jan 12, 2025
pulisher
Jan 11, 2025

Intellia Therapeutics, Inc. Announces Executive Changes - Marketscreener.com

Jan 11, 2025
pulisher
Jan 11, 2025

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital - Yahoo Finance

Jan 11, 2025
pulisher
Jan 11, 2025

Insider Sellers Might Regret Selling Intellia Therapeutics Shares at a Lower Price Than Current Market Value - Simply Wall St

Jan 11, 2025
pulisher
Jan 11, 2025

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo - Yahoo Finance

Jan 11, 2025
pulisher
Jan 11, 2025

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga

Jan 11, 2025
pulisher
Jan 10, 2025

Wedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA) - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Peering Into Intellia Therapeutics's Recent Short Interest - Benzinga

Jan 10, 2025
pulisher
Jan 10, 2025

Gene editing stocks drop as Intellia announces layoffs - MSN

Jan 10, 2025
pulisher
Jan 10, 2025

Why Is Intellia Therapeutics Stock Trading Lower On Friday? - Yahoo Finance

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia stock hits 52-week low at $11.34 amid market challenges By Investing.com - Investing.com South Africa

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low After Analyst Downgrade - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia cuts 27% of workforce as it eyes commercial launch - The Business Journals

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $50.00 at BMO Capital Markets - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia stock hits 52-week low at $11.34 amid market challenges - Investing.com

Jan 10, 2025
pulisher
Jan 10, 2025

Wells Fargo & Company Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia to stop work on rare disease therapy, lay off staff - BioPharma Dive

Jan 10, 2025
pulisher
Jan 10, 2025

CRISPR gene editing company cuts program and jobs - The Pharma Letter

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia Therapeutics Restructures to Focus on Late-Stage Programs - TipRanks

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia Therapeutics stock falls following strategic reorganization - Investing.com

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia Therapeutics stock falls following strategic reorganization By Investing.com - Investing.com Australia

Jan 10, 2025
pulisher
Jan 10, 2025

CRISPR biotech Intellia cuts staff as it eyes 2027 launch - pharmaphorum

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia to cut 27% of workforce, discontinue NTLA-3001 - MSN

Jan 10, 2025
pulisher
Jan 09, 2025

Intellia to cut 27% of workforce, discontinue NTLA-3001 (NTLA:NASDAQ) - Seeking Alpha

Jan 09, 2025

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Intellia Therapeutics Inc (NTLA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
BASTA JAMES
EVP, General Counsel
Jan 03 '25
Sale
12.18
7,074
86,161
74,497
Lebwohl David
EVP, Chief Medical Officer
Jan 03 '25
Sale
12.18
9,557
116,404
87,666
Hicks Derek
EVP, Chief Business Officer
Jan 03 '25
Sale
12.18
6,502
79,194
59,878
LEONARD JOHN M
President and CEO
Jan 03 '25
Sale
12.18
26,807
326,509
941,115
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Jan 03 '25
Sale
12.18
8,966
109,206
77,388
Clark Eliana
EVP, Chief Technical Officer
Jan 03 '25
Sale
12.18
7,422
90,400
64,048
Clark Eliana
EVP, Chief Technical Officer
Jan 02 '25
Sale
12.03
556
6,689
71,470
Dube Michael P
VP, Chief Accounting Officer
Oct 02 '24
Sale
19.01
2,012
38,248
47,012
Clark Eliana
EVP, Chief Technical Officer
Jul 01 '24
Sale
22.93
405
9,287
71,470
Verwiel Frank
Director
Jun 17 '24
Sale
25.00
1,505
37,625
17,948
$30.75
price down icon 0.65%
$71.93
price down icon 0.75%
$19.03
price up icon 4.62%
$358.93
price down icon 2.04%
biotechnology ONC
$210.08
price up icon 2.31%
$111.93
price down icon 0.74%
大文字化:     |  ボリューム (24 時間):